Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-015-0195-4
Keywords
-
Categories
Funding
- Shaoxing People's Hospital, Zhejiang Province, China
- Henan Provincial Grant for Overseas Research for Young Leaders of Medical Technology [2014041]
- Division of Hematology and Oncology, New York Medical College, USA
- Natural Science Foundation of China (NSFC) [81201793]
Ask authors/readers for more resources
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor (e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
